Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorLacerenza, S.
dc.contributor.authorMoura, D.
dc.contributor.authorPena-Chilet, M.
dc.contributor.authorHindi, N.
dc.contributor.authorDopazo, J.
dc.contributor.authorSanchez-Bustos, P.
dc.contributor.authorGrignani, G.
dc.contributor.authorMartinez-Trufero, J.
dc.contributor.authorRedondo, A.
dc.contributor.authorValverde, C.
dc.contributor.authorStacchiotti, S.
dc.contributor.authorLopez-Pousa, A.
dc.contributor.authorD'Ambrosio, L.
dc.contributor.authorPerez-Vega, H.
dc.contributor.authorCollini, P.
dc.contributor.authorLopez-Martin, J. A.
dc.contributor.authorMartin-Broto, J.
dc.contributor.authoraffiliation[Lacerenza, S.] Inst Biomed Seville IBiS, Seville, Spain
dc.contributor.authoraffiliation[Moura, D.] Inst Biomed Seville IBiS, Seville, Spain
dc.contributor.authoraffiliation[Lacerenza, S.] US, HUVR, CSIC, Seville, Spain
dc.contributor.authoraffiliation[Moura, D.] US, HUVR, CSIC, Seville, Spain
dc.contributor.authoraffiliation[Sanchez-Bustos, P.] US, HUVR, CSIC, Seville, Spain
dc.contributor.authoraffiliation[Pena-Chilet, M.] Hosp Virgen Rocio, Clin Bioinformat Area, Seville, Spain
dc.contributor.authoraffiliation[Dopazo, J.] Hosp Virgen Rocio, Clin Bioinformat Area, Seville, Spain
dc.contributor.authoraffiliation[Hindi, N.] Fdn Jimenez Diaz Univ Hosp, Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Sanchez-Bustos, P.] Inst Biomed Seville IBiS, Oncohematol & Genet Dept, Seville, Spain
dc.contributor.authoraffiliation[Grignani, G.] FPO IRCCS, Candiolo Canc Inst, Div Med Oncol, Turin, Italy
dc.contributor.authoraffiliation[D'Ambrosio, L.] FPO IRCCS, Candiolo Canc Inst, Div Med Oncol, Turin, Italy
dc.contributor.authoraffiliation[Martinez-Trufero, J.] HU Miguel Servet, Med Oncol, Zaragoza, Spain
dc.contributor.authoraffiliation[Redondo, A.] La Paz Univ Hosp, Madrid, Spain
dc.contributor.authoraffiliation[Valverde, C.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Stacchiotti, S.] Ist Nazl Tumori Milano Fdn IRCCS, Canc Med Dept, Adult Mesenchymal Tumor Med Oncol Unit, Milan, Italy
dc.contributor.authoraffiliation[Lopez Pousa, A.] Hosp Santa Creu & Sant Pau, Barcelona, Spain
dc.contributor.authoraffiliation[Perez-Vega, H.] Hosp Virgen Rocio, Seville, Spain
dc.contributor.authoraffiliation[Collini, P.] IRCCS Ist Nazl Tumori, Dipartimento Patol Diagnost & Lab, Milan, Italy
dc.contributor.authoraffiliation[Lopez-Martin, J. A.] Hosp 12 Octubre, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Martin Broto, J.] Fdn Jimenez Diaz Univ Hosp, Med Oncol, Madrid, Spain
dc.contributor.funderSarcoma Foundation of America - SFA
dc.date.accessioned2025-01-07T15:51:26Z
dc.date.available2025-01-07T15:51:26Z
dc.date.issued2021-09-21
dc.description.abstractImmunomodulation has emerged as an active therapeutic option in some solid tumors; however, the efficacy of immunotherapy-based regimens is limited in sarcomas or restricted to a few specific subtypes. IMMUNOSARC was a phase Ib/II trial testing the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab) in bone and soft-tissue sarcoma (STS). In this latter cohort, the trial met its primary endpoint, with 48% of patients free of progression at 6 months (m). We present here, part of the correlative studies associated with the STS cohort.
dc.description.versionNo
dc.identifier.citationLacerenza, S., Moura, D., Pena-Chilet, M., Hindi, N., Dopazo, J., Sanchez-Bustos, P., et al. Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups. Ann. Oncol; 2021-09-21; (32); S1118
dc.identifier.doi10.1016/j.annonc.2021.08.866
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.866
dc.identifier.urihttps://hdl.handle.net/10668/27455
dc.identifier.wosID700527703083
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS1118-S1118
dc.provenanceRealizada la curación de contenido 26/03/2025
dc.publisherElsevier
dc.relation.publisherversionannalsofoncology.org/article/S0923-7534(21)03095-7/fulltext
dc.rights.accessRightsRestricted Access
dc.subjectHumans
dc.subjectProgrammed Cell Death 1 Receptor
dc.subjectImmunotherapy
dc.subjectAngiogenesis
dc.subject.decsSarcoma
dc.subject.decsEficacia
dc.subject.decsHuesos
dc.subject.decsSunitinib
dc.subject.decsPacientes
dc.subject.decsInmunoterapia
dc.subject.decsTejidos
dc.subject.decsTerapéutica
dc.subject.meshB7-H1 Antigen
dc.subject.meshNivolumab
dc.subject.meshSunitinib
dc.subject.meshSarcoma
dc.subject.meshImmunomodulation
dc.titleBiological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía